This finding aligns with a meta-analysis by Anagnostou et al., which reviewed 35 clinical trials of anti-CD19 CAR T-cell therapy for patients with relapsed/refractory acute lymphoblastic leukemia (ALL), showing grade 3 or higher CRS and ICANS in 26% and 12% of cases, respectively (88). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.